CPTAC

Myriad RBM is collaborating with researchers at the Max Planck Institute of Biochemistry and the Bavarian Red Cross Blood Donor BioBank to identify protein biomarkers for the early detection of colon cancer.

The National Cancer Institute's Clinical Proteomic Technologies for Cancer Initiative this week issued a request for targets for monoclonal antibody production and characterization as part of its Antibody Characterization Program.

By Adam Bonislawski

By Adam Bonislawski

By Adam Bonislawski

This story originally ran on Oct. 6

By Adam Bonislawski
Theranostics Health has licensed a new fixative developed by researchers at George Mason University that could significantly improve the quality of tissue samples available to proteomic researchers.

This story originally ran on Aug. 22 and has been updated to include comments from a participant.
By Adam Bonislawski

BGI, which, according to an official, generated roughly $6.2 million in proteomics revenue last year, plans to buy around 15 new high-resolution machines and 30 to 40 triple quadrupoles as part of its efforts to expand into the clinical proteomics and pharma markets.

The company, called SISCAPA Assay Technologies, will offer assay development to pharmas and CROs and has tapped antibody firm Epitomics to produce reagents for the system and sell SISCAPA kits. So far, the company has licensed the technology to Pfizer for internal use.